NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 04/21/2022 18:41
Last Report Issued 05/04/2013 13:31

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 4114SP-POS
Patient ID 4114SP-POS
Chain 13001798
DOB Not Given
Sex Not Given
Workorder 13001798

Received 05/04/2013

Lab ID 13001798-001
Matrix Serum or Plasma
Patient Name 4114SP-POS
Patient ID 4114SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
4114SP Rivaroxaban, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Rivaroxaban	5000	ng/mL	0.50	ELEVATED

Synonym(s): Xarelto®

Mean peak plasma concentrations of rivaroxaban following a single oral administration of 5, 10, or 20 mg oral doses are as follows:
5 mg: 67.2 ng/mL [range, 53.2 to 81.2]
10 mg: 143 ng/mL [range, 110 to 175]
20 mg: 204 ng/mL [range, 179 to 229]

Mean peak plasma concentrations of rivaroxaban at steady state following a multi-dose administration of 5, 10, or 20 mg oral doses every 12 hours are as follows:

5 mg: 115 ng/mL [range, 91.1 to 139]
10 mg: 215 ng/mL [range, 178 to 252]
20 mg: 415 ng/mL [range, 355 to 474]

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.